603520.SS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 04:40):

Stats
Dzisiejszy wolumen	904 460
Średni wolumen	7.79M
Kapitalizacja rynkowa	4.20B
EPS	CNY0 ( 2023-10-30 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-72.18
ATR14	CNY0.0170 (0.14%)

Wolumen Korelacja

Długi: 0.78 (moderate)

Krótki: 0.50 (weak)

Signal:(86.803) Neutral

Zhejiang Starry Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Zhejiang Starry Korelacja - Waluta/Towar

0.34
( neutral )

0.33
( neutral )

0.00
( neutral )

0.14
( neutral )

0.31
( neutral )

-0.23
( neutral )

Zhejiang Starry Finanse

Annual	2022
Przychody:	CNY2.13B
Zysk brutto:	CNY512.45M (24.04 %)
EPS:	CNY-0.210

FY	2022
Przychody:	CNY2.13B
Zysk brutto:	CNY512.45M (24.04 %)
EPS:	CNY-0.210

FY	2021
Przychody:	CNY2.00B
Zysk brutto:	CNY747.98M (37.40 %)
EPS:	CNY1.320

FY	2020
Przychody:	CNY1.37B
Zysk brutto:	CNY601.36M (43.99 %)
EPS:	CNY1.000

Financial Reports:

No articles found.

Zhejiang Starry

Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.